one missing item on websiteI wish somewhere they would put that they had a CRR of over 35% on Pappilary. Carcinoma InSitu was 20%, but that is only 10% of the population base, whereas 90% are Pappilary. That means over a third of the most prevalent patients will be cured. When factoring in adding MCNA as an adjuvant at immediate post Turbt setting that number jumps up almost to around 50%. SUMMARY? MCNA is not only the most efficacious by country mile (less than 10% effective for Valstar and highly toxic) and MCNA is well tolerated with less than 1.5% of patient experiencing mild to moderate side effects. Don't think for a second partners or acquirers are not well aware MCNA. It's only a matter of time with multiple term sheets in play that something very big big is going to happen. Next halt will be a bIggy. Hope you are loaded up ...i know i am. GLTA beech